CommercialCoverageMedium impact
05.00.77f, Implantable Cardioverter Defibrillators
Independence Blue Cross·PA · Cardiology, Cardiothoracic Surgery, Critical Care·Medical Policy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Summary
Independence Blue Cross updated Medical Policy 05.00.77f to version 05.00.77g, expanding coverage to address transvenous, subcutaneous, and extravascular implantable cardioverter defibrillators (ICDs). The policy reissued on 04/01/2026 communicates the Company's continuing position on ICD coverage. Transvenous and subcutaneous ICDs remain covered when medical necessity criteria are met; extravascular ICDs remain experimental/investigational and not covered.
Action Required
By 04/01/2026: Billing team must verify that billing system recognizes the updated policy version 05.00.77g for ICD procedures. Update internal policy references and prior authorization templates to reflect the reissued policy. Confirm that claims for transvenous and subcutaneous ICDs (CPT 33216, 33217, 33218, 33220, 33223, 33230, 33240, 33241 and HCPCS C1721, C1722, C1895, C1896) continue to process under existing medical necessity criteria. Ensure that any claims for extravascular ICDs are denied with the rationale that the service is experimental/investigational and not covered. Providers should continue to submit documentation supporting medical necessity for covered ICD types. Failure to update system references may result in processing delays or incorrect claim handling.